2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 177

Treatment with Dexamethasone and Monophosphoryl Lipid a Removes Disease-Associated Transcriptional Signatures in Monocyte-Derived Dendritic Cells from Rheumatoid Arthritis Patients and Confers the Ability to Modulate CD4+ T Cell Responses
Abstract Number: 178

Alpha-Enolase Promotes Pro-Inflammatory Phenotype of Monocytes-Derived Macrophages
Abstract Number: 179

CD11b+Gr1dimcells, Which Are Induced By GM-CSF Produced By Th17 and Group3 Innate Lymphoid Cell, May Facilitate the Progression of Pneumonitis in SKG Mice
Abstract Number: 180

WITHDRAWN
Abstract Number: 181

Functional and Quantitative Changes of CCR6+ type3 Innate Lymphoid Cells in Murine Collagen-Induced Arthritis
Abstract Number: 182

Histone Methylation in γδ T Cells As a Biomarker of Behcet’s Disease Activity
Abstract Number: 183

Protective Role of Mucosal-Associated Invariant T (MAIT) Cells in an Imiquimod-Induced Psoriasis Model
Abstract Number: 184

Upregulation and Activation of the IFI16-Sting-IRF3-IFN Pathway in Sjogren’s Salivary Glands
Abstract Number: 185

The Interferon Gene Signature Is Increased in Early DMARD Naive Rheumatoid Arthritis and Predicts a Poorer Response to Initial Therapy
Abstract Number: 186

Impact of TLR Stimulation on Cytokine Production in Macrophage Subsets: TLR2 Stimulation Impairs Anti-Inflammatory Activity of M2 Macrophages
Abstract Number: 187

Commensal Microbiota Tune Systemic Toll-like Receptor-Mediated Inflammatory Responses
Abstract Number: 188

Responsiveness to X-Linked Toll-like Receptors Differs Between Mice with XY and XX Sex Chromosome Complement, Regardless of the Gonadal Sex
Abstract Number: 189

Nutraceutical Therapy with Polyphenol-Rich Pomegranate Fruit Extract (POMx) Inhibits Systemic NFκB-Mediated Inflammation in a Murine Model of Endotoxemia
Abstract Number: 190

Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Adult Male Subjects
Abstract Number: 191

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Febuxostat in Healthy Adult Male Subjects

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].